Evidence map›Paper›PMID 41593776›Full record

ArticleJournal of ovarian research2026

Proteomic analysis of ovarian carcinoma reveals diagnostic and prognostic biomarkers with histotype- and stage-specificity.

Lucas Werner, Ella Ittner, Hugo Swenson, Elisabeth Werner Rönnerman, Claudia Mateoiu, Anikó Kovács, Pernilla Dahm-Kähler, Per Karlsson, Toshima Z Parris, Khalil Helou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucas WernerDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. lucas.werner@gu.se.
Ella IttnerDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Hugo SwensonDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Elisabeth Werner RönnermanDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Claudia MateoiuDepartment of Clinical Pathology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.
Anikó KovácsDepartment of Clinical Pathology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.
Pernilla Dahm-KählerDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Per KarlssonDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Toshima Z ParrisDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Khalil HelouDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpithelial ovarian cancer (EOC) is the deadliest gynecologic cancer, due to asymptomatic early stages, vague symptoms in later stages, and limited clinical tools. Despite distinct clinicopathologic features, all EOC histotypes typically receive identical primary treatment, and are often studied as a single entity.

methodsWe analyzed the proteome of 244 patients and identified differentially abundant proteins (DAPs) with and without stage specificity across histotypes and constructed panels of DAPs to distinguish histotypes in both early and late stages. Survival analysis was performed to find proteins associated with clinical outcomes, and enrichment analysis was conducted to reveal biological processes connected to prognosis and the proteins involved.

resultsHere we find DAPs without (e.g. S100A1, AGR2, CTH) and with (TSPYL, VWA2, GPC6, S100P) stage-specificity for each histotype. Survival analysis revealed histotype- and stage-specific prognostic markers (e.g., EXO3CL2, PPIL6, GYG1, GAPDH), while biological process enrichment highlighted pathways underlying clinical outcomes.

conclusionsOur findings provide novel diagnostic and prognostic biomarker candidates and insights into mechanisms driving EOC progression with histotype- and stage-specificity. This may aid the development of improved clinical tools for detection, patient stratification, and targeted therapies in EOC.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialOvarian NeoplasmsAdultAgedAged, 80 and overCohort StudiesFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm StagingOvaryPrognosisProteomeProteomicsBiomarkers, TumorProteome

Identifiers

PMID41593776
PMCPMC12924536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.